Your browser doesn't support javascript.
loading
An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population.
Fochesato, Anna; Sottile, Sara; Pugliese, Andrea; Márquez-Peláez, Sergio; Toro-Diaz, Hector; Gani, Ray; Alvarez, Piedad; Ruiz-Aragón, Jesús.
Afiliação
  • Fochesato A; Department of Mathematics, University of Trento, Via Sommarive 14, 38123 Trento, Italy.
  • Sottile S; Fondazione The Microsoft Research-University of Trento, Centre for Computational and Systems Biology (COSBI), Piazza Manifattura 1, 38068 Rovereto, Italy.
  • Pugliese A; Department of Mathematics, University of Trento, Via Sommarive 14, 38123 Trento, Italy.
  • Márquez-Peláez S; Department of Mathematics, University of Trento, Via Sommarive 14, 38123 Trento, Italy.
  • Toro-Diaz H; Department of Economics, Faculty of Business, Universidad Pablo de Olavide, 41013 Sevilla, Spain.
  • Gani R; Evidence, Modeling and Synthesis, Evidera, Waltham, MA 02451, USA.
  • Alvarez P; Evidence, Modeling, and Synthesis, Evidera, London W6 8BJ, UK.
  • Ruiz-Aragón J; Evidence, Modeling, and Synthesis, Evidera, London W6 8BJ, UK.
Vaccines (Basel) ; 10(8)2022 Aug 20.
Article em En | MEDLINE | ID: mdl-36016247
ABSTRACT
Standard-dose quadrivalent influenza vaccines (QIV) are designed to provide protection against all four influenza strains. Adjuvanted QIV (aQIV), indicated for individuals aged 65+ years, combines MF59® adjuvant (an oil-in-water emulsion of squalene oil) with a standard dose of antigen, and is designed to produce stronger and longer immune response, especially in the elderly where immunosenescence reduces vaccine effectiveness. This study evaluated the cost-effectiveness of aQIV vs. egg-based standard-dose QIV (QIVe) in the elderly population, from the payer and societal perspective in Spain. A dynamic transmission model, which accounts for herd protection, was used to predict the number of medically attended infections in Spain. A decision tree structure was used to forecast influenza-related costs and benefits. Influenza-related probabilities of outpatient visit, hospitalization, work absenteeism, mortality, and associated utilities and costs were extracted from Spanish and European published literature. Relative vaccine effectiveness (rVE) was sourced from two different meta-analyses the first meta-analysis was informed by laboratory-confirmed influenza studies only, resulting in a rVE = 34.6% (CI95% 2-66%) in favor of aQIV; the second meta-analysis included real world evidence influenza-related medical encounters outcomes, resulting in a rVE = 13.9% (CI95% 4.2-23.5%) in benefit of aQIV. All costs were expressed in 2021 euros. Results indicate that replacing QIVe with aQIV in the Spanish elderly population would prevent on average 43,664 influenza complicated cases, 1111 hospitalizations, and 569 deaths (with a rVE = 34.6%) or 19,104 influenza complicated cases, 486 hospitalizations, and 252 deaths (with a rVE = 13.9%). When the rVE of aQIV vs. QIVe is 34.6%, the incremental cost per quality adjusted life years (QALY) gained was €2240 from the payer; from the societal perspective, aQIV was cost saving compared with QIVe. If the rVE was 13.9%, the incremental cost per QALY was €6694 and €3936 from the payer and societal perspective, respectively. Sensitivity analyses validated the robustness of these findings. Results indicate that replacing QIVe with aQIV in the Spanish elderly population is a cost-effective strategy for the Spanish healthcare system.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article